American Journal of Pharmacology

Review Article
Published: 23 Jan, 2019

Vasculogenic Mimicry and Its Role in Cancer

Anurag Chaudhary, Neeru Singh, Vipin Kumar G and Mansi Verma*

Department of Pharmaceutical Technology, Meerut Institute of Engineering and Technology, India

Abstract

It has been found that, on inhibition of angiogenesis, many tumors develop alternative strategies for self-supply with nutrients. One of these strategies is Vasculogenic Mimicry. Vasculogenic Mimicry (VM) is *de novo* formation of perfusable, matrix-rich, vasculogenic-like networks by aggressive tumour cells. The initial morphologic and molecular characterization of VM was made in human melanoma in which the tumour cells were shown to co-express endothelial and tumour markers and formed channels, networks, and tubular structures that are rich in laminin, collagens IV and VI, and heparin sulphate proteoglycans, containing plasma and red blood cells, indicating a perfusion pathway for rapidly growing tumors, as well as an escape route for metastasis. Vascular mimicry was originally located in melanoma. It has since been observed in many tumors including hepatocellular carcinoma, gastric adenocarcinoma, gall bladder carcinoma, ovarian cancer and prostate cancer. This review embodies the mechanism of VM, discovered so far, along with its effect on various tumors.

Keywords: Vasculogenic mimicry; Angiogenesis; Tumor proliferation; Antitumor; Cancer

Introduction

Cancer death principally outcome from metastases that is impenetrable to conventional therapies. Indeed, the received tenet underlying tumour endurance has been that a blood supply is necessary to maintain growth and to metastasize [1]. This significant hypothesis ignited the field of neoplastic angiogenesis research, which fixed on targeting endothelial cells forming the neo-vasculature of growing tumors, and served as the chief organizing standard for drug discovery and development and clinical trials. On the other hand, the unsatisfactory grades of the angiogenesis inhibitor trials, mutually with new conclusion generated from complicated animal models of human tumour development, have given us novel insights into the molecular mechanisms basic the perfusion of tumors, principally those expressing the destructive metastatic phenotype. One of the new paradigms that has emerged, called "Vascular Mimicry" (VM), also referred to as "Vasculogenic Mimicry" describes the *de novo* formation of perfusable, matrix-rich, vasculogenic-like networks by destructive tumour cells in 3-dimensional matrices *in vitro*, which parallels matrix-rich networks in patients' destructive tumors [2]. The primary morphologic and molecular description of VM was made in human melanoma in which the tumour cells were exposed to co-express endothelial and tumour markers and created channels, networks, and tubular structures that are loaded in laminin, collagens IV and VI, and heparin sulphate proteoglycans, containing plasma and red blood cells, representing a perfusion pathway for quickly growing tumors, as well as an escape way for metastasis [2-4]. Fascinatingly, these conclusions agree with very early intelligence by others telling the perfusion of melanoma tumors via non endothelial-lined channels [5]. In view of the fact that the beginning of VM, a excess of studies have contributed mechanistic insights into the initiation, configuration, and targeting of VM across a range of cancers, together with melanoma; sarcomas (Ewing, mesothelial, synovial, osteosarcoma, alveolar rhabdomyosarcoma); carcinomas of the breast, ovary, lung, prostate, urinary bladder, and kidney; and gliomas, glioblastoma, and astrocytoma [6-8]. From the wide invented story from corner to corner this huge pasture, we now be glad about that the tumour vasculature is extremely intricate and can be plagiaristic from a range of sources, together with angiogenic vessels, cooption of pre-existing vessels, intussusceptive micro vascular development, mosaic vessels ruled by both tumour cells and endothelium, postnatal vasculogenesis, and VM [9,10]. Moreover, modern studies have exposed the tumour foundation of endothelial- like cells in exact cancers [11,12]. As a consequence mystifying our strategies for targeting a hereditarily unsteady and varied vasculature.

Functional Relevance of Vascular Mimicry

The existence of VM in patients' tumour tissues has been connected with a deprived clinical

OPEN ACCESS

Correspondence:
Anurag Chaudhary, Department of Pharmaceutical Technology, Meerut Institute of Engineering and Technology, NH-58, Bypass Road, Meerut, 250005, India
Tel: +919917062681;
E-mail: anurag15182@rediffmail.com

Received Date: *07 Jan 2019*
Accepted Date: *21 Jan 2019*
Published Date: *23 Jan 2019*

Citation:
Anurag, Singh N, Vipin Kumar G, Verma M. Vasculogenic Mimicry and Its Role in Cancer. Am J Pharmacol. 2019; 2(1): 1013.

conclusion and suggests a potential improvement imparted by VM with respect to the endurance of the violent tumour cell phenotype. To be sure, experimental confirmation has exposed a physiologic perfusion of blood among endothelial-lined mouse vasculature and VM networks in human tumour xenografts with Doppler imaging of micro bead transmission [13]. Supplementary studies acknowledged the anticoagulant properties of tumour cells that procession VM networks, discussed below the caption of "Vascular Signalling Pathways drawn in Vascular Mimicry". Therefore, VM can grant a functional perfusion pathway for quickly rising tumors by transporting fluid from spongy vessels and/or involving with endothelial-lined vasculature. A significant example of VM functional flexibility was achieved *via* transplanting human metastatic melanoma cells interested in a circulation-deficient mouse limb, which resulted in the configuration of a human melanoma mouse endothelial chimeric neo-vasculature [14]. Consequent to the reinstallation of blood flow to the limb, the tumour cells created a large tumour mass. Hence, this study tinted the prevailing control of the microenvironment on the trans-endothelial separation of melanoma cells that reverted to a tumorigenic phenotype as the environmental cues changed.

Vascular Signalling Pathways Involved in Vascular Mimicry

One of the primary vascular-connected genes exposed to be implicated in VM is VE-cadherin (CDH5). VE-cadherin is a trans-membrane glycoprotein of the cadherin relatives that promotes homotypic cell–cell interactions and is well thought-out exact for vascular endothelia and crucial for vasculogenic trial. Fascinatingly, VE-cadherin is articulated in violent, but not nonviolent melanoma cells, and knock over of VE-cadherin appearance inhibits VM [15]. VE-cadherin regulates erythropoietin-producing hepatic cellular carcinoma-A2 (EphA2) action via mediating its skill to be converted into phosphorylated through relations with its membrane-bound ligand Ephrin-A1 [16]. VEGF-A is one of a relatives of five angiogenic development factors that plays a crucial role in tumour angiogenesis by recruiting and motivating the production of endothelial cells in a vascular regions of quickly rising tumors. VM is dependent on the autocrine construction of VEGF-A in melanoma [17]. In mammary and pancreatic islet carcinoma cells, embarrassment of EphA2 appearance and/or activity leads to a decrease in VEGF appearance and VEGF-induced angiogenesis *in vivo* [18]. This suggests that, depending scheduled the tumour cell type, VEGF signalling or EphA2 foundation may grant the initiating occasion in VM configuration, Although additional studies are necessary to exclusively deal with this opportunity. In accumulation to EphA2 and COX-2 can also up regulate VEGF appearance in a diversity of tumour cell types *via* launch of protein kinase C [19,20]. COX-2 catalyzes the exchange of arachidonic acid into prostaglandin H2, which is consequently transformed into mainly prostaglandin E2 (PGE2). COX-2 and PGE2 are up regulated in violent cancers and are linked with reduce in cellular apoptosis and enhance in tumour proliferation, invasion, and angiogenesis. These processes are mediated *via* the relatives of prostanoid receptors (EP1-4), which trigger EGF Receptor (EGFR) mediated signalling, in addition to PKC-dependent creation of extracellular signal-regulated kinase [21]. Pigment Epithelium-Derived Factor (PEDF) is a multifunctional, veiled glycoprotein that is division of the non-inhibitory relations of serine protease inhibitors. PEDF has straight (*via* suppressing development by promoting tumour isolation and apoptosis) and circumlocutory (*via* suppressing angiogenesis by inducing apoptosis *via* FasL appearance and inhibiting VEGF signalling through VEGFR1) antitumor property [22]. Tissue Factor (TF), TF Pathway Inhibitor 1 (TFPI-1), and TFPI-2 are typical genes that begin and control coagulation pathways, and all 3 of these genes are up regulated in violent melanoma cells [13].

Vasculogenic Mimicry in Prostate Cancer

Prostate Cancer (PCa) is the mainly universally diagnosed tumour in males and is subsequent barely to lung cancer as a chief cause of cancer-related deaths in western countries [23]. Treatment options for restricted PCa are radical surgery and radiation, and on behalf of tumours that are not restricted to the prostate, Androgen Deprivation Therapy (ADT). However, within an average of 18 months, the majority of patients with metastatic syndrome ultimately evolution to ADT-resistant PCa, for which no valuable therapies subsist [24,25]. Hence, innovative therapeutic approaches to highly developed PCa are immediately requisite. It is well recognized that violent tumour development depends on a diversity of distinctive mechanisms. For example, to certify enough nutrient deliver, tumours discharge angiogenic factors that encourage neo-vascularisation, signifying that reserve of angiogenesis might be a dominant therapeutic approach in controlling extreme tumour growth. However, this approach though broadly applied in many tumours, frequently unsuccessful to supply acceptable grades and was mostly ineffective when applied to proceed PCa [26,27]. This recommended that tumours have substitute strategies for self-supply with nutrients. One of these strategies is vasculogenic mimicry. VM was initially exposed in melanoma. It has given that many tumours counting hepatocellular carcinoma, gastric adenocarcinoma, gall bladder carcinoma, ovarian cancer, and PCa [28-32]. VM is categorized by the capability of violent tumour cells to straight form a blood vessel-like network with associations to regular or spongy blood vessels. In accumulation, VM may perhaps also gather as a way for metastatic distribution of tumour cells [33]. As VM is sponsor by intra tumoral hypoxia, the on top of mentioned anti-angiogenic therapy can guide to an adverse enlarge in VM [34,35]. Hence, treatment strategies designed at cutting off blood supply to superior PCa should goal both endothelium-dependent vessels and VM. As a result, it is significant to analyze the underlining mechanisms of PCa VM from its beginning to its concluding form in order to design rational therapeutic strategies for superior PCa.

Vasculogenic Mimicry in Gastrointestinal Stromal Tumour

Much attention has been paid to the role of angiogenesis during cancer progression. In this context, neoplastic cells are able to show vasculogenic mimicry [36,37]. The vasculogenic mimicry phenotype facilitates tumour perfusion without the participation of angiogenesis, due to the ability of cancer cell plasticity. Immunohistochemical and electron microscopic examinations have provided evidence of the absence of vascular endothelial cells in the interface between tumour cells and blood perfusion [38]. In addition, vasculogenic mimicry has been observed in various malignancies, including carcinomas arising in the gastrointestinal tract, breast, prostate, and ovary, as well as melanoma and soft tissue sarcomas [36-40]. Gastrointestinal Stromal Tumour (GIST) is the largely familiar mesenchymal neoplasm of the gastrointestinal tract, and it spans a clinical band from benign to malignant [41]. Only one report has shown that vasculogenic mimicry was observed in 21 (25%) of 84 GIST cases, but morphological features were not described [42].

Vasculogenic Mimicry in Hepatocellular Carcinoma

Hepatocellular Carcinoma (HCC) is an excited vascular concrete tumour that principally exhibits abnormal angiogenesis. Preceding studies indicated that barely endothelial cells could form blood vessels to support the growth of malignant tumours; however, recent studies have exposed numerous novel patterns by which tumour tissues encourage themselves. These patterns include the formation of a pattern of mosaic vessels from endothelium and tumour cells and the generation of channels lined exclusively with tumour cells which is known as vasculogenic mimicry [43,44]. Tumour cells coating of HCC conceal Matrix Metallo Proteinases (MMP) and communicate Vascular Endothelial (VE) cadherin to encourage extracellular matrix, which showed that VM occurs in HCC and that EMT might exist occupied in VM formation in HCC (45-47). Earlier investigate statistics indicated that VM was experimental in 18 out of 97 patients with HCC [45]. Twist, one of the transcription factors that control EMT, was detected in 13 of the 18 samples (72%) in the VM-positive group. *In vitro* bend up instruction leads to improved HCC cell incursion, immigration, and VM configuration [45]. Some studies have too established that EMT and VM are connected with reduced clinical diagnosis in patients [48,49]. However, few studies have investigated inhibitors of these processes [50].

Vasculogenic Mimicry in Pancreatic Cancer

Along with other tumours VM has also been observed in pancreatic cancer [51-59]. 59 Most recent studies have shown that Vascular Endothelial-cadherin (VE-cadherin), epithelial cell kinase (EphA2), and Matrix Metallo Proteinase (MMPs) play a crucial role in VM formation in pancreatic cancer [60-68]. Thus, regulation of VM formation could be a novel cancer therapy strategy against human cancers, including pancreatic cancer.

Vasculogenic Mimicry in Glioblastoma

Glioblastoma (GBM) is the generally ordinary and toxic malignant brain tumour in adults. It is an extraordinarily violent malignancy categorized by broad microvascular propagation and is extremely challenging to exhaustive grouping therapies. The prediction for GBM patients is particularly reduced although the use of inclusive treatment linking coarse tumour resection, chemotherapy and/or radiotherapy, with a common life expectation of 12 to 15 months once diagnosed [69,70]. GBM is one of the mainly vascularised tumours, and its deprived diagnosis principally grades from its enveloping properties. Indeed, a traditional opinion primary tumour endurance is that a blood convey is necessary to maintain development and attack [71,72]. The neoplastic angiogenesis research ignited by investigators was the basis for enthusiastic preclinical trials, which ultimately reaped disappointing clinical results [73]. Thus, investigators established that tumour perfusion mechanisms are much supplementary complicated than they formerly realized [71]. Since the innovation of VM, collective studies have contributed fresh insights into the fundamental molecular pathways following its survival in a diversity of non-melanoma violent tumours, together with GBM [74-82].

Vasculogenic Mimicry in Human Gallbladder Carcinomas

Gallbladder Carcinoma (GBC) is the most common Biliary Tract Cancer (BTC), the fifth or sixth common malignant neoplasm of the digestive tract and the leading cause of cancer-related deaths in West countries and China [83-87]. It frequently presents at a complex phase, and has partial therapeutic options such as squat surgical resection rate, inadequate chemotherapy and radiotherapy; additionally, indicative delay, high local reappearance and isolated metastasis, and organic manners of the tumour, the projection is very deprived [83,88-95]. The development and metastasis of the tumour depend on efficient microcirculation. The configuration of a microcirculation occurs through the conventionally acknowledged mechanisms of vasculogenesis and angiogenesis and the newly found vasculogenic mimicry [96,97]. To review, it has been glowing recognized that tumours need a blood deliver for development and haematogenous propagation; consequently, researchers have purposeful on endothelial cells, which form the neovasculature of mounting tumours. Though, angiogenesis may not be the solitary mechanism by which tumours obtain their microcirculation [98]. In 1999, Manicottis and colleagues, for the former time, described a procedure by which tumour cells enlarge extremely attractive vascular channels by means of reorientation of the F-acting cytoskeleton and matrix remodelling without the participation of endothelial cells and fibroblasts [40]. These vascular-like structures are composed of a vault membrane optimistic for episodic acid-Schiff (PAS) discoloration and contribute in tumour perfusion [46]. This method was distinct as Vasculogenic Mimicry (VM). VM has been reported to be linked with extra violent tumour manners [99-101]. Theoretically, VM, lacking the obstruction of endothelial cells, is a further suitable metastasis route [102].

Future Directions

VM was too establishing to be related to deprived clinical outcomes, and this discovery might incompletely clarify why several tumours counter badly to angiogenesis inhibitors [103]. In addition, a modern *In vitro* revision examined the position of VM in stem cell ambitious spheroid configuration [104]. This conclusion encouraged us to discover the therapeutic potential of targeting the tumour VM. The useful flexibility of violent cancer cells is supposed to be involved in VM tube configuration [105-109]. Escalating proof suggests that Rho GTPases are necessary for cell plasticity. These kinases are established in virtually all eukaryotic cells, where they exchange connecting the inactive GDP-bound and the dynamic GTP-bound states. These kinases have been occupied in a broad collection of cellular processes, including cytoskeleton dynamics, cell polarity, contraction, adhesion, migration, propagation, and apoptosis all of which might be occupied in carcinogenesis [110,111]. Further investigation is required in this area to find various pathways involved in VM, which may help to develop more effective antitumor agents.

References

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182-6.
2. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LMG, Pe'er J, et al. Vascular channel formation by human melanoma cells *in vivo* and *in vitro*: vasculogenic mimicry. Am J Pathol. 1999;155(3):739-52.
3. Folberg R, Hendrix MJ, Maniotis AJ. Vasculogenic mimicry and tumor angiogenesis. Am J Pathol. 2000;156(2):361-81.
4. Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix MJC, et al. Molecular classification of cutaneous malignant melanoma by gene expression: Shifting from a continuous spectrum to distinct biologic entries. Nature. 2000;406(6795):536-40.

5. Warren BA, Shubik P. The growth of the blood supply to melanoma transplants in the hamster cheek pouch. Lab Invest. 1966;15(2):464-78.
6. Paulis YWJ, Soetekouw PM, Verheul HMW, Tjan-Heijnen VCG, Griffioen AW. Signalling pathways in vasculogenic mimicry. Biochim Biophys Acta. 2010;1806(1):18-28.
7. Hendrix MJ, Seftor EA, Hess AR, Seftor RE. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer. 2003;3(6):411-21.
8. El Hallani S, Boisselier B, Peglion F, Rousseau A, Colin C, Idbaih A, et al. A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry. Brain. 2010;133(4):973-82.
9. Dome B, Hendrix MJC, Paku S, T_ov_ari J, Tím_ar J. Alternative vascularisation mechanisms in cancer: Pathology and therapeutic implications. Am J Pathol. 2007;170(1):1-15.
10. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473(7347):298-307.
11. Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G, Cenci T, et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature. 2010;468(7325):824-8.
12. Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, Geber A, et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature. 2010;468(7325):829-33.
13. Ruf W, Seftor EA, Petrovan RJ, Weiss RM, Gruman LM, Margaryan NV, et al. Differential role of tissue factor pathway inhibitors 1 and 2 in melanoma vasculogenic mimicry. Cancer Res. 2003;63(17):5381-9.
14. Hendrix MJC, Seftor REB, Seftor EA, Gruman LM, Lee LM, Nickoloff BJ. Transendothelial function of human metastatic melanoma cells: role of the microenvironment in cell-fate determination. Cancer Res. 2002;62(3):665-8.
15. Hendrix MJC, Seftor EA, Meltzer PS, Gardner LMG, Hess AR, Kirschmann DA, et al. Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc Natl Acad Sci U S A. 2001;98(14):8018-23.
16. Hess AR, Margaryan NV, Seftor EA, Hendrix MJC. Deciphering the signaling events that promote melanoma tumor cell vasculogenic mimicry and their link to embryonic vasculogenesis: role of the Eph receptors. Dev Dyn. 2007;236(12):3283-96.
17. Vartanian A, Stepanova E, Grigorieva I, Solomko E, Baryshnikov A, Lichinitser M. VEGFR1 and PKCa signaling control melanoma vasculogenic mimicry in a VEGFR2 kinase-independent manner. Melanoma Res. 2011;21(2):91-8.
18. Cheng N, Brantley D, Fang WB, Liu H, Fanslow W, Cerretti DP, et al. Inhibition of VEGF-dependent multistage carcinogenesis by soluble EphA receptors. Neoplasia. 2003;5(5):445-56.
19. Brantley-Sieders DM, Fang WB, Hwang Y, Hicks D, Chen J. Ephrin-A1 facilitates mammary tumor metastasis through an angiogenesis-dependent mechanism mediated by EphA receptor and vascular endothelial growth factor in mice. Cancer Res. 2006;66(21):10315-24.
20. Luo H, Chen Z, Jin H, Zhuang M, Wang T, Su C, et al. Cyclooxygenase-2 up-regulates vascular endothelial growth factor via a protein kinase C pathway in non-small cell lung cancer. J Exp Clin Cancer Res. 2011;30(1):6.
21. Wu WKK, Sung JJY, Lee CW, Yu J, Cho CH. Cyclooxygenase-2 in tumorigenesis of gastrointestinal cancers: an update on the molecular mechanisms. Cancer Lett. 2010;295(1):7-16.
22. Hoshina D, Abe R, Yamagishi SI, Shimizu H. The role of PEDF in tumor growth and metastasis. Curr Mol Med. 2010;10(3):292-5.
23. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med. 2003;349(4):366-81.
24. Bubendorf L, Schöpfer A, Wagner U, Sauter G, Moch H, Willi N, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Human pathol. 2000;31(5):578-83.
25. Gittes RF. Carcinoma of the prostate. New Engl J Med. 1991;324(4):23645.
26. Adesunloye BA, Karzai FH, Dahut WL. Angiogenesis inhibitors in the treatment of prostate cancer. Chem Immunol Allergy. 2014;99:197-215.
27. Hwang C, Heath IE. Angiogenesis inhibitors in the treatment of prostate cancer. J Hematol Oncol. 2010;3:26.
28. Li M, Gu Y, Zhang Z, Zhang S, Zhang D, Saleem AF, et al. Vasculogenic mimicry: a new prognostic sign of gastric adenocarcinoma. Pathol Oncol Res. 2010;16(2):259-66.
29. Liu WB, Xu GL, Jia WD, Li JS, Ma JL, Chen K, et al. Prognostic significance and mechanisms of patterned matrix vasculogenic mimicry in hepatocellular carcinoma. Med Oncol. 2011;28(1):S228-38.
30. Sood AK, Fletcher MS, Coffin JE, Yang M, Seftor EA, Gruman LM, et al. Functional role of matrix metalloproteinases in ovarian tumor cell plasticity. Am J Obstet Gynecol. 2004;190(4):899-909.
31. Sun W, Shen ZY, Zhang H, Fan YZ, Zhang WZ, Zhang JT, et al. Overexpression of HIF-1alpha in primary gallbladder carcinoma and its relation to vasculogenic mimicry and unfavourable prognosis. Oncol Rep. 2012;27(6):1990-2002.
32. Liu R, Yang K, Meng C, Zhang Z, Xu Y. Vasculogenic mimicry is a marker of poor prognosis in prostate cancer. Cancer Biol Ther. 2012;13(7):527-33.
33. Seftor RE, Hess AR, Seftor EA, Kirschmann DA, Hardy KM, Margaryan NV, et al. Tumor cell vasculogenic mimicry: from controversy to therapeutic promise. Am J Pathol. 2012;181(4):1115-25.
34. Qu B, Guo L, Ma J, Lv Y. Antiangiogenesis therapy might have the unintended effect of promoting tumor metastasis by increasing an alternative circulatory system. Med Hypotheses. 2010;74(2):360-1.
35. Xu Y, Li Q, Li XY, Yang QY, Xu WW, Liu GL. Short-term anti-vascular endothelial growth factor treatment elicits vasculogenic mimicry formation of tumors to accelerate metastasis. J Exp Clin Cancer Res. 2012;31(1):16.
36. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe'er J, et al. Vascular channel formation by human melanoma cells *in vivo* and *in vitro*: vasculogenic mimicry. Am J Pathol. 1999;155(3):739-52.
37. Folberg R, Hendrix MJ, Maniotis AJ. Vasculogenic mimicry and tumor angiogenesis. Am J Pathol. 2000;156(2):361-81.
38. Shirakawa K, Tsuda H, Heike Y, Kato K, Asada R, Inomata M, et al. Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer. Cancer Res. 2001:61(2):445-51.
39. Sood AK, Seftor EA, Fletcher MS, Gardner LM, Heidger PM, Buller RE, et al. Molecular determinants of ovarian cancer plasticity. Am J Pathol. 2001;158(4):1279-88.
40. Li M, Gu Y, Zhang Z, Zhang D, Saleem AF, Zhao X, et al. Vasculogenic mimicry: a new prognostic sign of gastric adenocarcinoma. Pathol Oncol Res. 2010;16(2):259-66.
41. Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO Classification of Tumours of the Digestive Systems. 4th Ed. WHO; 2010. p.417.
42. Sun B, Qie S, Zhang S, Sun T, Zhao X, Gao S, et al. Role and mechanism of vasculogenic mimicry in gastrointestinal stromal tumors. Hum Pathol. 2008;39(3):444-51.
43. Sun B, Zhang D, Zhang S, Zhang W, Guo H, Zhao X. Hypoxia influences vasculogenic mimicry channel formation and tumor invasion-related protein expression in melanoma. Cancer Lett. 2007;249(2):188-97.

44. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe'er J, et al. Vascular channel formation by human melanoma cells *in vivo* and *in vitro*: vasculogenic mimicry. Am J Pathol. 1999;155(3):739-52.

45. Sun T, Zhao N, Zhao XL, Gu Q, Zhang SW, Che N, et al. Expression and functional significance of Twist1 in hepatocellular carcinoma: its role in vasculogenic mimicry. Hepatology. 2010;51(2):545-56.

46. Sun B, Zhang S, Zhang D, Du J, Guo H, Zhao X. Vasculogenic mimicry is associated with high tumor grade, invasion and metastasis, and short survival in patients with hepatocellular carcinoma. Oncol Rep. 2006;16(4):693-8.

47. Fan YL, Zheng M, Tang YL, Liang XH. A new perspective of vasculogenic mimicry: EMT and cancer stem cells (Review). Oncol Lett. 2013;6(5):1174-80.

48. Paterlini-Brechot P, Benali NL. Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett. 2007;253(2):180-204.

49. Paulis YW, Soetekouw PM, Verheul HM, Tjan-Heijnen VC, Griffioen AW. Signalling pathways in vasculogenic mimicry. Biochim Biophys Acta. 2010;1806(1):18-28.

50. Tong M, Han BB, Holpuch AS, Pei P, He L, Mallery SR. Inherent phenotypic plasticity facilitates progression of head and neck cancer: Endotheliod characteristics enable angiogenesis and invasion. Exp Cell Res. 2013;319(7):1028-42.

51. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe'er J, et al. Vascular channel formation by human melanoma cells *in vivo* and *in vitro*: vasculogenic mimicry. Am J Pathol. 1999;155(3):739-52.

52. Wang W, Lin P, Han C, Cai W, Zhao X, Sun B. Vasculogenic mimicry contributes to lymph node metastasis of laryngeal squamous cell carcinoma. J Exp Clin Cancer Res. 2010;29:60.

53. Millimaggi D, Mari M, D' Ascenzo S, Giusti I, Pavan A, Dolo V. Vasculogenic mimicry of human ovarian cancer cells: role of CD147. Int J Oncol. 2009;35(6):1423-8.

54. Clemente M, Pérez-Alenza MD, Illera JC, Peña L. Histological, immunohistological, and ultrastructural description of vasculogenic mimicry in canine mammary cancer. Vet Pathol. 2010;47(2):265-74.

55. Cai XS, Jia YW, Jiong M, Tang RY. Tumor blood vessels formation in osteosarcoma: vasculogenesis mimicry. Chin J Med. 2004;117(1):94-8.

56. Yue WY, Chen ZP. Does vasculogenic mimicry exist in astrocytoma? J Histochem Cytochem. 2005;53(8):997-1002.

57. Sun W, Fan YZ, Zhang WZ, Ge CY. A pilot histomorphology and hemodynamic of vasculogenic mimicry in gallbladder carcinomas *in vivo* and *in vitro*. J Exp Clin Cancer Res. 2011;30(1):46.

58. Yue WY, Chen ZP. Vasculogenic mimicry--potential target for tumor therapy. Ai Zheng. 2006;25(7):914-6.

59. Shirakawa K, Kobayashi H, Heike Y, Kawamoto S, Brechbiel MW, Kasumi F, et al. Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft. Cancer Res. 2002;62(2):560-6.

60. Hendrix MJ, Seftor EA, Meltzer PS, Gardner LM, Hess AR, Kirschmann DA, et al. Expression and functional signiicance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc Natl Acad Sci USA. 2001;98(14):8018-23.

61. Hess AR, Seftor EA, Gruman LM, Kinch MS, Seftor RE, Hendrix MJ. VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: implica¬tions for vasculogenic mimicry. Cancer Biol Ther. 2006;5(2):228-33.

62. Hess AR, Seftor EA, Gardner LM, Carles-Kinch K, Schneider GB, Seftor RE, et al. Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2). Cancer Res. 2001;61(8):3250-5.

63. Margaryan NV, Strizzi L, Abbott DE, Seftor EA, Rao MS, Hendrix MJ, et al. EphA2 as a promoter of melanoma tumorigenicity. Cancer Biol Ther. 2009;8(3):279-88.

64. Hess AR, Margaryan NV, Seftor EA, Hendrix MJ. Deciphering the signaling events that promote melanoma tumor cell vasculogenic mimicry and their link to embryonic vasculogenesis: role of the Eph receptors. Dev Dyn. 2007;236(12):3283-96.

65. Seftor RE, Seftor EA, Koshikawa N, Meltzer PS, Gardner LM, Bilban M, et al. Cooperative interactions of laminin 5 gamma 2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res. 2001;61(17):6322-7.

66. Seftor RE, Seftor EA, Kirschmann DA, Hendrix MJ. Targeting the tumor microenvironment with chemically modified tetracyclines: inhibition of laminin 5 gamma 2 chain promigratory fragments and vasculogenic mimicry. Mol Cancer Ther. 2002;1(13):1173-9.

67. Hess AR, Seftor EA, Seftor RE, Hendrix MJ. Phosphoinositide 3-kinase regulates membrane type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry. Cancer Res. 2003;63(16):4757-62.

68. Sood AK, Fletcher MS, Coffin JE, Yang M, Seftor EA, Gruman LM, et al. Functional role of matrix metalloproteinases in ovarian tumor cell plasticity. Am J Obstet Gynecol. 2004;190(4):899-909.

69. Wang SY, Ke YQ, Lu GH, Song ZH, Yu L, Xiao S, et al. Vasculogenic mimicry is a prognostic factor for postoperative survival in patients with glioblastoma. J Neurooncol. 2013;112(3):339-45.

70. Soda Y, Myskiw C, Rommel A, Verma IM. Mechanisms of neovascularisation and resistance to anti-angiogenic therapies in glioblastoma multiforme. J Mol Med (Berl). 2013;91(4):439-48.

71. Plate KH, Scholz A, Dumont DJ. Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited. Acta Neuropathol. 2012;124(6):763-75.

72. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8(8):592-603.

73. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe'er J, et al. Vascular channel formation by human melanoma cells *in vivo* and *in vitro*: vasculogenic mimicry. Am J Pathol. 1999;155(3):739-52.

74. Fausto N. Vasculogenic mimicry in tumors. Fact or artifact? Am J Pathol. 2000;156(2):359.

75. Hendrix MJ, Seftor EA, Hess AR, Seftor RE. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer. 2003;3(6):411-21.

76. Shirakawa K, Wakasugi H, Heike Y, Watanabe I, Yamada S, Saito K, et al. Vasculogenic mimicry and pseudo-comedo formation in breast cancer. Int J Cancer. 2002;99(6):821-8.

77. Sood AK, Fletcher MS, Zahn CM, Gruman LM, Coffin JE, Seftor EA. The clinical significance of tumor cell-lined vasculature in ovarian carcinoma: implications for anti-vasculogenic therapy. Cancer Biol Ther. 2002;1(6):661-4.

78. Fan YZ, Sun W, Zhang WZ, Ge CY. Vasculogenic mimicry in human primary gallbladder carcinoma and clinical significance thereof. Zhonghua Yi Xue Za Zhi. 2007;87(3):145-9.

79. Guzman G, Cotler SJ, Lin AY, Maniotis AJ, Folberg R. A pilot study of vasculogenic mimicry immunohistochemical expression in hepatocellular carcinoma. Arch Pathol Lab Med. 2007;131(12):1776-81.

80. Zhao H, Gu XM. Study on vasculogenic mimicry in malignant esophageal stromal tumors. World J Gastroenterol. 2008;14(15):2430-3.

81. Vartanian AA, Stepanova EV, Gutorov SL, Solomko E, Grigorieva IN,

Sokolova IN. Prognostic significance of periodic acid-Schiff-positive patterns in clear cell renal cell carcinoma. Can J Urol. 2009;16(4):4726-32.

82. Yue WY, Chen ZP. Does vasculogenic mimicry exist in astrocytoma? J Histochem Cytochem. 2005;53(8):997-1002.

83. Gourgiotis S, Kocher HM, Solaini L, Yarollahi A, Tsiambas E, Salemis NS. Gallbladder cancer. Am J Surg. 2008;196(2):252-64.

84. Lazcano-Ponce EC, Miquel JF, Muñoz N, Herrero R, Ferrecio C, Wistuba II, et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin. 2001;51(6):349-64.

85. Reddy SK, Clary BM. Surgical management of gallbladder cancer. Surg Oncol Clin N Am. 2009;18(2):307-24.

86. Li LD, Zhang SW, Lu FZ, Mu R, Sun XD, Huangpu XM. Research on characteristics of mortality spectrum and type composition of malignant tumors in China. Zhonghua Zhongliu Zazhi. 1997;19(5):323-8.

87. Hsing AW, Gao YT, Devesa SS, Jin F, Fraumeni JF Jr. Rising incidence of biliary tract cancers in Shanghai, China. Int J Cancer. 1998;75(3):368-70.

88. Chakravarty KD, Yeh CN, Jan YY, Chen MF. Factors influencing long-term survival in patients with T3 gallbladder adenocarcinoma. Digestion. 2009;79(3):151-7.

89. Konstantinidis IT, Deshpande V, Genevay M, Berger D, Fernandez-del Castillo C, Tanabe KK, et al. Trends in presentation and survival for gallbladder cancer during a period of more than 4 decades: a single-institution experience. Arch Surg. 2009;144(5):441-7.

90. Ishii H, Furuse J, Yonemoto N, Nagase M, Yoshino M, Sato T. Chemotherapy in the treatment of advanced gallbladder cancer. Oncology. 2004;66(2):138-42.

91. Morise Z, Sugioka A, Tanahashi Y, Okabe Y, Ikeda M, Kagawa T, et al. Treatment of patients with unresectable advanced carcinoma of biliary tract chemotherapy and surgical resection. Anticancer Res. 2009;29(5):1783-6.

92. Mahantshetty UM, Palled SR, Engineer R, Homkar G, Shrivastava SK, Shukla PJ. Adjuvant radiation therapy in gallbladder cancers: 10 years experience at Tata Memorial Hospital. J Cancer Res Ther. 2006;2(2):52-6.

93. Mojica P, Smith D, Ellenhorn J. Adjuvant radiation therapy is associated with improved survival for gallbladder carcinoma with regional metastatic disease. J Surg Oncol. 2007;96(1):8-13.

94. Shukla PJ, Barreto SG. Gall bladder cancer: we need to do better! Ann Surg Oncol. 2009;16(8):2084-5.

95. McNamara MG, Metran-Nascente C, Knox JJ. State-of-the-art in the management of locally advanced and metastatic gallbladder cancer. Curr Opin Oncol. 2013;25(4):425-31.

96. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe'er J, et al. Vascular channel formation by human melanoma cells *in vivo* and *in vitro*: vasculogenic mimicry. Am J Pathol. 1999;155(3):739-52.

97. Warso MA, Maniotis AJ, Chen X, Majumdar D, Patel MK, Shilkaitis A, et al. Prognostic significance of periodic acid-Schiff-positive patterns in primary cutaneous melanoma. Clin Cancer Res. 2001;7(3):473-7.

98. Shirakawa K, Wakasugi H, Heike Y, Watanabe I, Yamada S, Saito K, et al. Vasculogenic mimicry and pseudo-comedo formation in breast cancer. Int J Cancer. 2002;99(6):821-8.

99. Baeten CI, Hillen F, Pauwels P, de Bruine AP, Baeten CG. Prognostic role of vasculogenic mimicry in colorectal cancer. Dis Colon Rectum. 2009;52(12):2028-35.

100. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med. 1995;333(26):1757-63.

101. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LMG, Pe'er J. Vascular channel formation by humanmelanoma cells *in vivo* and *in vitro*: vasculogenic mimicry. Am J Pathol. 1999;155(3):739-52.

102. Folberg R, Hendrix MJ, Maniotis AJ. Vasculogenic mimicry and tumor angiogenesis. Am J Pathol. 2000;156(2):361-81.

103. Vartanian AA. Signaling pathways in tumor vasculogenic mimicry. Biochemistry (Mosc). 2012;77(9):1044-55.

104. Sun B, Zhang S, Zhao X, Zhang W, Hao X. Vasculogenic mimicry is associated with poor survival in patients with mesothelial sarcomas and alveolar rhabdomyosarcomas. Int J Oncol. 2004;25(6):1609-14.

105. Chung HJ, Mahalingam M. Angiogenesis, vasculogenic mimicry and vascular invasion in cutaneous malignant melanoma implications for therapeutic strategies and targeted therapies. Expert Rev Anticancer Ther. 2014;14(5):621-39.

106. Paulis YW, Soetekouw PM, Verheul HM, Tjan-Heijnen VC, Griffioen AW. Signalling pathways in vasculogenic mimicry. Biochim Biophys Acta. 2010;1806(1):18-28.

107. Kirschmann DA, Seftor EA, Hardy KM, Seftor RE, Hendrix MJ. Molecular pathways: vasculogenic mimicry in tumor cells: diagnostic and therapeutic implications. Clin Cancer Res. 2012;18(10):2726-32.

108. Larson AR, Lee CW, Lezcano C, Zhan Q, Huang J, Fischer AH. Melanoma spheroid formation involves laminin-associated vasculogenic mimicry. Am J Pathol. 2014;184(1):71-8.

109. Maes H, Van Eygen S, Krysko DV, Vandenabeele P, Nys K, Rillaerts K, et al. BNIP3 supports melanoma cell migration and vasculogenic mimicry by orchestrating the actin cytoskeleton. Cell Death Dis. 2014;5:e1127.

110. Matsui T, Amano M, Yamamoto T, Chihara K, Nakafuku M, Ito M, et al. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J. 1996;15(9):2208-16.

111. Murali A, Rajalingam K. Small Rho GTPases in the control of cell shape and mobility. Cell Mol Life Sci. 2014;71(9):1703-21.